Clinical trial · Observational
Analysis of Computed Tomography Derived Maps for Determining Changes of the Liver Volume After Exposure to Radiotherapy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Radiotherapy is commonly used to treat cancers involving the liver or nearby organs. While effective, radiation exposure can affect healthy liver tissue and may lead to changes in liver size and function. Monitoring these changes is important to improve treatment planning and reduce the risk of liver-related complications. This study aims to evaluate changes in liver volume using computed tomography (CT) imaging before and after radiotherapy. By analyzing CT-derived liver maps, the study seeks to better understand how the liver responds to radiation treatment over time. The study will include patients who undergo radiotherapy and have CT imaging performed as part of their routine clinical care. No additional procedures or treatments will be required for participation. The findings of this study may help improve future radiotherapy planning and patient monitoring by providing better information on liver volume changes following radiation exposure.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Intra-abdominal Malignancies | — | UNRESOLVED | — |
| Liver as Organ at Risk | — | UNRESOLVED | — |
| Radiation-related Liver Changes | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Change in Liver Volume After Radiotherapy
- timeFrame
- Liver volume changes will be assessed at post-treatment intervals, typically at 1, 3, and 6 months after radiotherapy. If only a single post-treatment scan is available, evaluation will occur approximately 3 months after treatment completion.
- description
- The primary outcome is the quantitative change in liver volume measured using computed tomography (CT) imaging before and after radiotherapy. Liver volume will be assessed using standard imaging software and protocols, and changes will be calculated relative to baseline.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
1. Inclusion criteria: * Adults aged 18 years or older. * Received radiation therapy (RT) involving the liver (e.g., SBRT, IMRT). The study involves patients in whom the liver was exposed to radiotherapy, either as a direct target (in hepatic-directed treatments as in HCC or liver metastasis) or indirectly as an organ-at-risk (OAR) during irradiation of nearby anatomical regions (as lower lung, gastric, or abdominal sites) where the liver was partially included within the radiation field. The analysis aims to evaluate radiation-induced volumetric changes regardless of whether the liver was the primary target or secondarily affected. * Availability of paired pre- and post-RT CT scans of sufficient quality. * 3D dose distribution data from the RT treatment plan. * Clinical follow-up data, including liver function tests and toxicity records. * No evidence of major anatomical changes between scans unrelated to RT (e.g., surgery). 2. Exclusion criteria: * Patients with a history of major liver surgery (e.g., resection or transplant) between the pre- and post-RT scans. * Presence of severe motion artifacts or poor-quality CT scans that hinder accurate image analysis. * Incomplete or missing 3D radiation dose distribution data. * Lack of sufficient clinical follow-up information (e.g., liver function tests, toxicity outcomes). * Concurrent systemic therapies (e.g., chemotherapy or immunotherapy) during the imaging interval that may confound liver volume changes, unless controlled for in analysis. * Pre-existing liver conditions that could independently alter liver volume (e.g., cirrhosis, advanced hepatic steatosis) if not accounted for. * Patients under 18 years of age.
References
Publications (0)
Data not yet available